“…Onge & Floresco, 2009). Methylphenidate and methamphetamine were included because these drugs have been used in commonly used delay-discounting tasks (e.g., Adriani et al, 2004; Evenden & Ryan, 1996; Pardey, Kumar, Goodchild, & Cornish, 2013; Paterson, Wetzler, Hackett, & Hanania, 2012; Pitts & Febbo, 2004; Richards, Sabol, & de Wit, 1999; Siemian, Xue, Blough, & Li, 2017; Slezak & Anderson, 2011; Tanno, Maguire, Henson, & France, 2014; van Gaalen, van Koten, Schoffelmeer, & Vanderschuren, 2006; Wade, de Wit, & Richards, 2000) as well as in concurrent-chains procedures (Maguire et al, 2009; Pitts et al, 2016; Ta et al, 2008) but have not been tested in probability discounting. Also, using these drugs is important as they are known to have high abuse potential in both preclinical (Baladi, Nielsen, Umpierre, Hanson, & Fleckenstein, 2014; Balster & Schuster, 1973; Collins, Weeks, Cooper, Good, & Russell, 1983; Harrod, Dwoskin, Crooks, Klebaur, & Bardo, 2001; Marusich & Bardo, 2009; Munzar, Baumann, Shoaib, & Goldberg, 1999; Pickens, 1968) and clinical populations (Reynolds, Strickland, Stoops, Lile, & Rush, 2017; Rush, Essman, Simpson, & Baker, 2001; Rush, Stoops, Lile, Glaser, & Hays, 2011; Stoops, Glaser, Fillmore, & Rush, 2004; see Stoops, 2008 for a review) and are known to alter risky decision making in humans (e.g., Campbell-Meiklejohn et al, 2012) or alter neural circuits related to risky decision making (Bischoff-Grethe et al, 2017; Ersche et al, 2005; Kohno, Morales, Ghahremani, Hellemann, & London, 2014).…”